Nuveen Asset Management LLC Has $4.67 Million Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Nuveen Asset Management LLC increased its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 495,727 shares of the biopharmaceutical company's stock after acquiring an additional 48,635 shares during the period. Nuveen Asset Management LLC owned approximately 1.01% of Theravance Biopharma worth $4,665,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. SG Americas Securities LLC grew its position in Theravance Biopharma by 21.1% in the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 3,349 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Theravance Biopharma by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after buying an additional 2,060 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in Theravance Biopharma in the 4th quarter valued at approximately $103,000. Magnetar Financial LLC raised its stake in Theravance Biopharma by 125.8% during the 4th quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after acquiring an additional 15,328 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in Theravance Biopharma by 11.9% during the 4th quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock worth $733,000 after acquiring an additional 8,289 shares during the period. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Stock Down 0.8%

NASDAQ TBPH traded down $0.09 on Wednesday, reaching $11.03. 68,000 shares of the stock traded hands, compared to its average volume of 275,705. Theravance Biopharma, Inc. has a 12 month low of $7.44 and a 12 month high of $11.82. The company has a market cap of $551.51 million, a price-to-earnings ratio of -10.93 and a beta of -0.10. The firm's fifty day simple moving average is $9.23 and its 200 day simple moving average is $9.37.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, equities research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on TBPH shares. Wall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $11.33.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares in the company, valued at $3,330,342. The trade was a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.